| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 12/17/2019 |
3. Issuer Name and Ticker or Trading Symbol
CATABASIS PHARMACEUTICALS INC [ CATB ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (1) | 09/07/2021 | Common Stock | 194 | 19.3 | D | |
| Stock Option (Right to Buy) | (1) | 12/18/2022 | Common Stock | 235 | 23.1 | D | |
| Stock Option (Right to Buy) | (1) | 12/18/2022 | Common Stock | 51 | 23.1 | D | |
| Stock Option (Right to Buy) | (1) | 12/18/2022 | Common Stock | 74 | 23.1 | D | |
| Stock Option (Right to Buy) | (1) | 04/17/2023 | Common Stock | 114 | 23.1 | D | |
| Stock Option (Right to Buy) | (1) | 03/19/2024 | Common Stock | 583 | 68.1 | D | |
| Stock Option (Right to Buy) | (1) | 02/12/2025 | Common Stock | 233 | 95.1 | D | |
| Stock Option (Right to Buy) | (1) | 03/25/2025 | Common Stock | 261 | 110.5 | D | |
| Stock Option (Right to Buy) | (2) | 02/10/2026 | Common Stock | 700 | 45.7 | D | |
| Stock Option (Right to Buy) | (3) | 09/07/2026 | Common Stock | 2,500 | 43.1 | D | |
| Stock Option (Right to Buy) | (4) | 02/08/2027 | Common Stock | 2,000 | 12.4 | D | |
| Stock Option (Right to Buy) | (5) | 07/26/2027 | Common Stock | 500 | 12.7 | D | |
| Stock Option (Right to Buy) | (6) | 02/07/2028 | Common Stock | 2,500 | 12.8 | D | |
| Stock Option (Right to Buy) | (7) | 09/06/2028 | Common Stock | 5,000 | 7.1 | D | |
| Stock Option (Right to Buy) | (8) | 02/12/2029 | Common Stock | 20,000 | 4.39 | D | |
| Explanation of Responses: |
| 1. Fully vested. |
| 2. This option was granted on February 11, 2016 and is subject to vesting over a four-year period, with 25% of the 700 shares underlying the option upon grant vesting on the first anniversary of February 11, 2016 and the remainder vesting over the ensuing three years in equal monthly installments. |
| 3. This option was granted on September 8, 2016 and is subject to vesting over a four-year period, with 25% of the 2,500 shares underlying the option upon grant vesting on the first anniversary of September 8, 2016 and the remainder vesting over the ensuing three years in equal monthly installments. |
| 4. This option was granted on February 9, 2017 and is subject to vesting over a four-year period, with 25% of the 2,000 shares underlying the option upon grant vesting on the first anniversary of February 9, 2017 and the remainder vesting over the ensuing three years in equal monthly installments. |
| 5. This option was granted on July 27, 2017 and is subject to vesting over a four-year period, with 25% of the 500 shares underlying the option upon grant vesting on the first anniversary of July 27, 2017 and the remainder vesting over the ensuing three years in equal monthly installments. |
| 6. This option was granted on February 8, 2018 and is subject to vesting over a four-year period, with 25% of the 2,500 shares underlying the option upon grant vesting on the first anniversary of February 8, 2018 and the remainder vesting over the ensuing three years in equal monthly installments. |
| 7. This option was granted on September 7, 2018 and is subject to vesting over a two-year period, with 50% of the 5,000 shares underlying the option upon grant vesting on the first anniversary of September 7, 2018 and the remainder vesting over the ensuing one year in equal monthly installments. |
| 8. This option was granted on February 13, 2019 and is subject to vesting over a four-year period, with 25% of the 20,000 shares underlying the option upon grant vesting on the first anniversary of February 13, 2019 and the remainder vesting over the ensuing three years in equal monthly installments. |
| Remarks: |
| Exhibit 24 - Power of Attorney. |
| /s/ Noah Clauser | 12/19/2019 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
LIMITED POWER OF ATTORNEY
FOR SECTION 16 REPORTING OBLIGATIONS
Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Jill C. Milne and Andrea Matthews, signing singly and each acting individually, as the undersigned’s true and lawful attorney-in-fact with full power and authority as hereinafter described to:
(1) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer of Catabasis Pharmaceuticals, Inc. (the “Company”), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the “Exchange Act”);
(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the “SEC”) and any stock exchange or similar authority, including without limitation the filing of a Form ID, Update Passphrase, or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;
(3) seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information regarding transactions in the Company’s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and
(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.
The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned’s responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of December 19, 2019.
|
|
/s/ Noah Clauser |
|
|
Noah Clauser |